 RADNOR, Pa., March 26, 2021 PRNewswire -- NeuroRx, Inc. announces completion of top line data analysis of the 60-day results in its phase 2b3 clinical trial, conducted under FDA Fast Track Designation, of ZYESAMITM aviptadil acetate for the treatment of critically-ill patients with COVID-19 respiratory failure 04311697. 